Good decisions require good information
Find hidden gems and smart strategies from top experts when you join Seeking Alpha.
APLS Apellis Pharmaceuticals, Inc.Stock Price & Overview
$41.15
Charts
Quant Ranking
APLS Analysis
APLS News
Latest Headlines
![Stephen Ayers profile picture](https://static1.seekingalpha.com/images/users_profile/048/050/289/big_pic.png?io=w36)
Ratings Summary
People Also Follow
Similar to APLS
ETFs Holding APLS
APLS Company Profile
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam’s base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.
APLS Revenue
APLS Earnings Per Share
Earnings Estimates
Earnings Revisions
Valuation
Growth
Profitability
Momentum
Capital Structure
Dividends
APLS Ownership
APLS Peers
Risk
Technicals
APLS Transcripts
Investor Presentations
APLS SEC Filings
Press Releases
APLS Income Statement
APLS Balance Sheet
APLS Cash Flow Statement
APLS Long Term Solvency
Discover More
You may be interested in: